133 related articles for article (PubMed ID: 8496812)
1. Cardioprotection in ischemic rat hearts with the SH-containing angiotensin-converting enzyme inhibitor zofenopril: possible involvement of the ATP-sensitive potassium channel.
Sargent CA; Sleph PG; Dzwonczyk S; Smith MA; Normandin D; Antonaccio MJ; Grover GJ
J Pharmacol Exp Ther; 1993 May; 265(2):609-18. PubMed ID: 8496812
[TBL] [Abstract][Full Text] [Related]
2. [ACE inhibitors with SH groups have no effect of ATP-dependent K channels--a dissertation].
Köppel H; Gasser R; Klein W; Holzmann S
Acta Med Austriaca; 1996; 23(3):109-12. PubMed ID: 8967287
[TBL] [Abstract][Full Text] [Related]
3. Protection of the ischemic myocardium by the converting-enzyme inhibitor zofenopril: insight into its mechanism of action.
Ferrari R; Cargnoni A; Curello S; Ceconi C; Boraso A; Visioli O
J Cardiovasc Pharmacol; 1992; 20(5):694-704. PubMed ID: 1280730
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotective effects of a novel calcium antagonist related to the structure of cromakalim.
Grover GJ; Sleph PG; Dzwonczyk S; McCullough JR
J Pharmacol Exp Ther; 1993 Oct; 267(1):102-7. PubMed ID: 8229736
[TBL] [Abstract][Full Text] [Related]
5. Effect of potassium channel blockade on the anti-ischemic actions of mechanistically diverse agents.
Sargent CA; Smith MA; Dzwonczyk S; Sleph PG; Grover GJ
J Pharmacol Exp Ther; 1991 Oct; 259(1):97-103. PubMed ID: 1920138
[TBL] [Abstract][Full Text] [Related]
6. Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening.
Grover GJ; D'Alonzo AJ; Hess T; Sleph PG; Darbenzio RB
Cardiovasc Res; 1995 Nov; 30(5):731-8. PubMed ID: 8595620
[TBL] [Abstract][Full Text] [Related]
7. Effects of cromakalim and glibenclamide on myocardial high energy phosphates and intracellular pH during ischemia-reperfusion: 31P NMR studies.
Docherty JC; Gunter HE; Kuzio B; Shoemaker L; Yang L; Deslauriers R
J Mol Cell Cardiol; 1997 Jun; 29(6):1665-73. PubMed ID: 9220352
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic characterization of BMS-191095, a mitochondrial K(ATP) opener with no peripheral vasodilator or cardiac action potential shortening activity.
Grover GJ; D'Alonzo AJ; Garlid KD; Bajgar R; Lodge NJ; Sleph PG; Darbenzio RB; Hess TA; Smith MA; Paucek P; Atwal KS
J Pharmacol Exp Ther; 2001 Jun; 297(3):1184-92. PubMed ID: 11356945
[TBL] [Abstract][Full Text] [Related]
9. Diabetes and ATP-sensitive potassium channel openers and blockers in isolated ischemic/reperfused hearts.
Tosaki A; Engelman DT; Engelman RM; Das DK
J Pharmacol Exp Ther; 1995 Dec; 275(3):1115-23. PubMed ID: 8531071
[TBL] [Abstract][Full Text] [Related]
10. Lack of a pharmacologic interaction between ATP-sensitive potassium channels and adenosine A1 receptors in ischemic rat hearts.
Grover GJ; Baird AJ; Sleph PG
Cardiovasc Res; 1996 Apr; 31(4):511-7. PubMed ID: 8689642
[TBL] [Abstract][Full Text] [Related]
11. Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotection.
Grover GJ; Sleph PG; Dzwonczyk S; Wang P; Fung W; Tobias D; Cushman DW
J Pharmacol Exp Ther; 1991 Jun; 257(3):919-29. PubMed ID: 1646329
[TBL] [Abstract][Full Text] [Related]
12. KATP channel opening does not contribute significantly to the vasodilatory effect of SH-group-containing ACE inhibitors.
Köppel H; Holzmann S; Klein W; Horn E; Horn S; Gasser R
Heart Vessels; 1996; 11(4):192-6. PubMed ID: 9119808
[TBL] [Abstract][Full Text] [Related]
13. KATP channel modulation in working rat hearts with coronary occlusion: effects of cromakalim, cicletanine, and glibenclamide.
Ferdinandy P; Szilvássy Z; Droy-Lefaix MT; Tarrade T; Koltai M
Cardiovasc Res; 1995 Nov; 30(5):781-7. PubMed ID: 8595627
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of ATP-sensitive potassium-channel openers in experimental myocardial ischemia.
Grover GJ
J Cardiovasc Pharmacol; 1994; 24 Suppl 4():S18-27. PubMed ID: 7898104
[TBL] [Abstract][Full Text] [Related]
15. ACE inhibition and protection from doxorubicin-induced cardiotoxicity in the rat.
Sacco G; Mario B; Lopez G; Evangelista S; Manzini S; Maggi CA
Vascul Pharmacol; 2009; 50(5-6):166-70. PubMed ID: 19344651
[TBL] [Abstract][Full Text] [Related]
16. The cardioprotective, vasorelaxant and electrophysiological profile of the large conductance calcium-activated potassium channel opener NS-004.
Sargent CA; Grover GJ; Antonaccio MJ; McCullough JR
J Pharmacol Exp Ther; 1993 Sep; 266(3):1422-9. PubMed ID: 8371147
[TBL] [Abstract][Full Text] [Related]
17. The cardioprotective and electrophysiological effects of cromakalim are attenuated by meclofenamate through a cyclooxygenase-independent mechanism.
Grover GJ; D'Alonzo AJ; Sleph PG; Dzwonczyk S; Hess TA; Darbenzio RB
J Pharmacol Exp Ther; 1994 May; 269(2):536-40. PubMed ID: 8182522
[TBL] [Abstract][Full Text] [Related]
18. Protective effects against hydrogen peroxide-induced toxicity by activators of the ATP-sensitive potassium channel in isolated rat hearts.
Gan XT; Cook MA; Moffat MP; Karmazyn M
J Mol Cell Cardiol; 1998 Jan; 30(1):33-41. PubMed ID: 9500862
[TBL] [Abstract][Full Text] [Related]
19. Cardioprotective profile of the cardiac-selective ATP-sensitive potassium channel opener BMS-180448.
Grover GJ; McCullough JR; D'Alonzo AJ; Sargent CA; Atwal KS
J Cardiovasc Pharmacol; 1995 Jan; 25(1):40-50. PubMed ID: 7723352
[TBL] [Abstract][Full Text] [Related]
20. Does captopril attenuate reperfusion-induced myocardial dysfunction by scavenging free radicals?
Westlin W; Mullane K
Circulation; 1988 Jun; 77(6 Pt 2):I30-9. PubMed ID: 2836109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
